Payment overview · 2025
General Payments
$2,348.47
37 reported records · 15 companies
Healthcare provider profile · identity verified
Dat Q Duong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · WESTMINSTER, CA · NPI 1689740912
Verified facts
What the public records show
CMS Open Payments records show Dat Q Duong, M.D. received $2,348.47 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tudorza Pressair by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 609 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 609 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $511.32 | 21.8% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $421.73 | 18.0% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $270.49 | 11.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $239.21 | 10.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $159.71 | 6.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $159.13 | 6.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $150.00 | 6.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $137.41 | 5.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $89.54 | 3.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.37 | 3.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.24 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.82 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.39 | 0.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.08 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.03 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,348.47 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $421.73 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $271.31 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $270.49 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $240.01 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $159.71 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $159.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $114.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $109.23 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $89.54 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $79.37 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.24 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 609 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 79 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
55 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
304 | 62 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
609 | 119 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
153 | 153 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
609 | 119 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pravastatin Sodium | Pravastatin Sodium | 1140 | 272 |
| Atorvastatin Calcium | Atorvastatin Calcium | 845 | 220 |
| Losartan Potassium | Losartan Potassium | 836 | 208 |
| Metoprolol Succinate | Metoprolol Succinate | 786 | 206 |
| Valsartan | Valsartan | 657 | 178 |
| Jardiance | Empagliflozin | 609 | 119 |
| Metformin Hcl | Metformin Hcl | 596 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 555 | 149 |
| Azithromycin | Azithromycin | 456 | 318 |
| Omeprazole | Omeprazole | 446 | 205 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 439 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 400 | 107 |
| Gabapentin | Gabapentin | 358 | 139 |
| Ezetimibe | Ezetimibe | 322 | 85 |
| Farxiga | Dapagliflozin Propanediol | 304 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 303 | 170 |
| Fluticasone Propionate | Fluticasone Propionate | 292 | 163 |
| Famotidine | Famotidine | 290 | 94 |
| Hydralazine Hcl | Hydralazine Hcl | 283 | 141 |
| Montelukast Sodium | Montelukast Sodium | 261 | 74 |
| Celecoxib | Celecoxib | 245 | 131 |
| Diclofenac Sodium | Diclofenac Sodium | 237 | 141 |
| Loperamide | Loperamide Hcl | 214 | 184 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 125 |
| Clopidogrel | Clopidogrel Bisulfate | 203 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 187 | 47 |
| Finasteride | Finasteride | 176 | 47 |
| Mirtazapine | Mirtazapine | 162 | 56 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 153 | 153 |
| Amoxicillin | Amoxicillin | 152 | 112 |
| Baclofen | Baclofen | 152 | 104 |
| Doxycycline Hyclate | Doxycycline Hyclate | 127 | 111 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 122 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 29 |
| Tradjenta | Linagliptin | 114 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 48 |
| Prednisone | Prednisone | 106 | 57 |
| Mupirocin | Mupirocin | 104 | 59 |
| Meloxicam | Meloxicam | 103 | 65 |
| Vascepa | Icosapent Ethyl | 102 | 22 |
| Hydrocortisone | Hydrocortisone | 99 | 60 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 23 |
| Alendronate Sodium | Alendronate Sodium | 97 | 32 |
| Atenolol | Atenolol | 97 | 24 |
| Allopurinol | Allopurinol | 96 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 31 |
| Memantine Hcl | Memantine Hcl | 95 | 23 |
| Lovastatin | Lovastatin | 90 | 23 |
| Colchicine | Colchicine | 87 | 40 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 86 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 69 |
| Eliquis | Apixaban | 79 | 16 |
| Kerendia | Finerenone | 79 | 15 |
| Lisinopril | Lisinopril | 78 | 21 |
| Meclizine Hcl | Meclizine Hcl | 78 | 50 |
| Januvia | Sitagliptin Phosphate | 72 | 15 |
| Benazepril Hcl | Benazepril Hcl | 68 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 66 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 20 |
| Tramadol Hcl | Tramadol Hcl | 65 | 27 |
| Fluocinonide | Fluocinonide | 63 | 34 |
| Icosapent Ethyl | Icosapent Ethyl | 63 | 19 |
| Linzess | Linaclotide | 57 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 11 |
| Doxepin Hcl | Doxepin Hcl | 55 | 20 |
| Prolia | Denosumab | 55 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 18 |
| Ketoconazole | Ketoconazole | 52 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 33 |
| Donepezil Hcl | Donepezil Hcl | 47 | 17 |
| Ozempic | Semaglutide | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 37 |
| Procto-Med Hc | Hydrocortisone | 44 | 28 |
| Felodipine Er | Felodipine | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | 13 |
| Levofloxacin | Levofloxacin | 37 | 32 |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Trospium Chloride | Trospium Chloride | 37 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 24 |
| Diltiazem 24hr Er | Diltiazem Hcl | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 15 |
| Entecavir | Entecavir | 32 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 32 | 27 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 12 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Restasis | Cyclosporine | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 17 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 14 |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Mitigare | Colchicine | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,348.47 · 37 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DUPIXENT, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error